What does the data on gliflozins say?
Type de matériel :
TexteLangue : français Détails de publication : 2023.
Sujet(s) : Ressources en ligne : Abrégé : The recent availability in France of two sodium-glucose co-transporter type 2 (SGLT2i) inhibitors, empagliflozin and dapagliflozin, both for the treatment of type 2 diabetes and heart failure with reduced ejection fraction, is based on very encouraging results from initial trials. They have also been shown to have a protective effect against the progression of kidney failure. These trials are consistent with real-life observations in countries where they were marketed earlier, with a reduction in all-cause mortality in particular.
Nous n'avons pas d'exemplaire de ce document
39
The recent availability in France of two sodium-glucose co-transporter type 2 (SGLT2i) inhibitors, empagliflozin and dapagliflozin, both for the treatment of type 2 diabetes and heart failure with reduced ejection fraction, is based on very encouraging results from initial trials. They have also been shown to have a protective effect against the progression of kidney failure. These trials are consistent with real-life observations in countries where they were marketed earlier, with a reduction in all-cause mortality in particular.
Réseaux sociaux